DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Longterm Follow-up of Patients in CSP Number 298 , Treatment of Patients with 'Acquired Immune Deficiency Syndrome (AIDS) and AIDS related Complex'.
Final rept. 1 Apr 91-30 Apr 94,
VETERANS ADMINISTRATION MEDICAL CENTER WASHINGTON DC
Pagination or Media Count:
To evaluate the benefits of early E vs. Later L ZDV therapy, we enrolled 338 symptomatic HIV patients with CD4 counts of 200-500cmm into a randomized, double-blind trial. Patients were assigned to initial ZDV 1,500 mgday E 168 pts or initial placebo L. 170 The latter were switched to ZDV after progression to AIDS or to a court 200cmm. All pts were offered ZDV 500 mgday following completion of blinded follow-up. Blinded and final follow-up were completed in January 1991 and 1994, respectively. Median follow-up was 52 months. Progressions to AIDS occurred in 67 and 84 pts in the E and L therapy groups, respectively rel. risk, 0.73 95 CI, 0.52- l.01 p 0.054. Death occurred in 74 and 73 pts in the E and L therapy groups, respectively rel. risk, 0.99 95 CI, 0.72-1.37 ns. We conclude that early compared with later ZDV provides marginal protection against progression to AIDS but no survival benefit.
APPROVED FOR PUBLIC RELEASE